반응식
[CH3:1][C:2]1[N:3]=[C:4]([C:17]([OH:19])=O)[S:5][C:6]=1[C:7]1[C:16]2[C:11](=[CH:12][CH:13]=[CH:14][CH:15]=2)[CH:10]=[CH:9][CH:8]=1.F[P-](F)(F)(F)(F)F.N1(O[P+](N(C)C)(N(C)C)N(C)C)C2C=CC=CC=2N=N1.[CH:47]([N:50]1[CH2:55][CH2:54][NH:53][CH2:52][CH2:51]1)([CH3:49])[CH3:48].CCN(CC)CC>C(Cl)Cl>[CH:47]([N:50]1[CH2:55][CH2:54][N:53]([C:17]([C:4]2[S:5][C:6]([C:7]3[C:16]4[C:11](=[CH:12][CH:13]=[CH:14][CH:15]=4)[CH:10]=[CH:9][CH:8]=3)=[C:2]([CH3:1])[N:3]=2)=[O:19])[CH2:52][CH2:51]1)([CH3:49])[CH3:48]참가 물질
6
반응물 4
생성물 1
시약·촉매·용매 1
실험 절차
To a solution of 4-methyl-5-naphthalen-1-yl-thiazole-2-carboxylic acid in methylene chloride (2 ml) is added BOP (44 mg, 0.10 mmol), isopropylpiperazine (13 mg, 0.10 mmol) and Et3N (20 mg, 0.20 mmol). The reaction mixture is stirred at rt for 2 hr. Solvent is removed and the resulting mixture is purified by PTLC to give the title compound. LC-MS M+1 380.03. 1H NMR δ (CDCl3) 7.90-7.96 (m, 2H), 7.68-7.72 (m, 1H), 7.46-7.56 (m, 4H), 4.51 (brs, 2H), 3.85 (brs, 2H), 2.77 (m, 1H), 2.67 (brs, 4H), 2.25 (s, 3H), 1.10 (d, 6H). LC-MS (M+1) 380.1.
후처리
- customSolvent is removed
- customthe resulting mixture is purified by PTLC
출처 및 근거
- ORD 기록
- ord-1fd45a014550457f9029f2a892cfb77e
- 출처 데이터셋
- uspto-grants-2010_06
- 특허 번호
- US07728009B1
연결된 노트
불러오는 중…